Dolutegravir/lamivudine/tenofovir
(Redirected from
Dolutegravir/lamivudine/tenofovir disoproxil
)Combination of | |
---|---|
Nucleoside reverse transcriptase inhibitor | |
Tenofovir disoproxil | Nucleoside reverse transcriptase inhibitor |
Clinical data | |
Other names | Tenofovir/lamivudine/dolutegravir (TLD) |
Routes of administration | By mouth |
ATC code | ) |
Dolutegravir/lamivudine/tenofovir (DTG/3TC/TDF) is a
Side effects may include
antiretroviral therapy.[2]
It is on the
generic medication.[5] It is tentatively approved in the United States as of 2019, full approval is pending expiration of the US patents on dolutegravir (Tivicay) and tenofovir disoproxil (Viread).[6][7]
Medical uses
As of 2019, it is listed by the
tenofovir/lamivudine/efavirenz as an alternative.[2] It may be used in people with both HIV and tuberculosis, however if the person is on rifampicin a larger dose of dolutegravir is needed.[2]
Side effects
Side effects may include
Society and culture
Economics
In the developing world it costs about US$75 per year.[8] It is considered more cost effective than tenofovir/lamivudine/efavirenz as of 2019.[2]
References
- ^ a b "Dolutegravir (DTG) and the fixed dose combination (FDC) of tenofovir/lamivudine/dolutegravir (TLD)" (PDF). World Health Organization (WHO). Retrieved 15 November 2019.
- ^ hdl:10665/325892. WHO/CDS/HIV/19.15; License: CC BY-NC-SA 3.0 IGO.
- ^ a b c d "WHO-PQ Recommended summary of product characteristics" (PDF). July 2019. Archived from the original (PDF) on November 16, 2019. Retrieved 16 November 2019.
- hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ^ "TDF/3TC/DTG" (PDF). Retrieved 16 November 2019.
- ^ "NDA 209618 Tentative Approval" (PDF). U.S. Food and Drug Administration (FDA). 25 March 2019. Retrieved 16 November 2019.
- ^ "NDA 210796 Tentative Approval" (PDF). U.S. Food and Drug Administration (FDA). 18 August 2017.
- S2CID 13674631.
External links
- "Dolutegravir". Drug Information Portal. U.S. National Library of Medicine.
- "Lamivudine". Drug Information Portal. U.S. National Library of Medicine.
- "Tenofovir disoproxil". Drug Information Portal. U.S. National Library of Medicine.
- "Tenofovir disoproxil fumarate". Drug Information Portal. U.S. National Library of Medicine.